Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream

• Main Authors: Michael D. Howell (Author), Fiona I. Kuo (Author), Beth Rumberger (Author), Erika Boarder (Author), Kang Sun (Author), Kathleen Butler (Author), John E. Harris (Author), Pearl Grimes (Author), David Rosmarin (Author)
• Format: Book
• Published: Elsevier, 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Efficacy of ruxolitinib cream, a topical Jak1/Jak2 inhibitor, was demonstrated in a phase 2 trial in patients with vitiligo. Objective: This study aimed to characterize circulating inflammatory biomarker profiles in patients who demonstrated ≥50% improvement in facial Vitiligo Area Scori...